References
- Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. https://doi.org/10.1038/nature05945
- Doebele RC, Camidge DR. Targeting ALK, ROS1, and BRAF kinases. J Thorac Oncol 2012;7(16 Suppl 5):S375-6. https://doi.org/10.1097/JTO.0b013e31826df05e
- Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012;76:403-9. https://doi.org/10.1016/j.lungcan.2011.11.008
- Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in nonsmall- cell lung cancer. N Engl J Med 2010;363:1693-703. https://doi.org/10.1056/NEJMoa1006448
- Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9. https://doi.org/10.1056/NEJMoa1007478
Cited by
- Chromosomal rearrangements in cancer : Detection and potential causal mechanisms vol.1, pp.1, 2014, https://doi.org/10.4161/mco.29904
- Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK vol.57, pp.4, 2013, https://doi.org/10.1021/acs.jcim.7b00019